Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Edelstein

Showing results (11-20 of 113) with videos related to

Pageof 12
Sort By:
Clinical Medicine Reviews in Oncology|April 29, 2014
Metastatic Renal Cancer: What Role for Everolimus?Franck A Belibi, Charles L Edelstein
Cellular Signalling|December 28, 2019
Apoptosis and autophagy in polycystic kidney disease (PKD)Kristen L Nowak, Charles L Edelstein
Hemodialysis International. International Symposium on Home Hemodialysis|November 21, 2007
Acute renal failure and chronic kidney disease following liver transplantationRajesh Yalavarthy, Charles L Edelstein, Isaac Teitelbaum
Mediators of Inflammation|February 26, 2010
Mediators of inflammation in acute kidney injuryAli Akcay, Quocan Nguyen, Charles L Edelstein
Kidney International Reports|April 30, 2025
Overview of ADPKD in PregnancyRuth E Campbell, Charles L Edelstein, Michel Chonchol
Therapeutic Drug Monitoring|March 19, 2019
Biomarkers of Drug-Induced Kidney ToxicityBenjamin R Griffin, Sarah Faubel, Charles L Edelstein
Journal of Toxicology|December 2, 2011
Biomarkers of acute kidney injuryJeffrey C Sirota, Jelena Klawitter, Charles L Edelstein
Renal Failure|October 14, 2014
A pan caspase inhibitor decreases caspase-1, IL-1α and IL-1β, and protects against necrosis of cisplatin-treated freshly isolated proximal tubulesDong Won Lee, Sarah Faubel, Charles L Edelstein
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 18, 2011
Clinical applications of biomarkers for acute kidney injuryJustin M Belcher, Charles L Edelstein, Chirag R Parikh
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2014
An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney diseaseKameswaran Ravichandran, Iram Zafar, Abdullah Ozkok, et al.
Pageof 12

Showing results (11-20 of 113) with videos related to

Sort By:
Pageof 12
Clinical Medicine Reviews in Oncology|April 29, 2014
Metastatic Renal Cancer: What Role for Everolimus?Franck A Belibi, Charles L Edelstein
Cellular Signalling|December 28, 2019
Apoptosis and autophagy in polycystic kidney disease (PKD)Kristen L Nowak, Charles L Edelstein
Hemodialysis International. International Symposium on Home Hemodialysis|November 21, 2007
Acute renal failure and chronic kidney disease following liver transplantationRajesh Yalavarthy, Charles L Edelstein, Isaac Teitelbaum
Mediators of Inflammation|February 26, 2010
Mediators of inflammation in acute kidney injuryAli Akcay, Quocan Nguyen, Charles L Edelstein
Kidney International Reports|April 30, 2025
Overview of ADPKD in PregnancyRuth E Campbell, Charles L Edelstein, Michel Chonchol
Therapeutic Drug Monitoring|March 19, 2019
Biomarkers of Drug-Induced Kidney ToxicityBenjamin R Griffin, Sarah Faubel, Charles L Edelstein
Journal of Toxicology|December 2, 2011
Biomarkers of acute kidney injuryJeffrey C Sirota, Jelena Klawitter, Charles L Edelstein
Renal Failure|October 14, 2014
A pan caspase inhibitor decreases caspase-1, IL-1α and IL-1β, and protects against necrosis of cisplatin-treated freshly isolated proximal tubulesDong Won Lee, Sarah Faubel, Charles L Edelstein
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 18, 2011
Clinical applications of biomarkers for acute kidney injuryJustin M Belcher, Charles L Edelstein, Chirag R Parikh
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2014
An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney diseaseKameswaran Ravichandran, Iram Zafar, Abdullah Ozkok, et al.
Pageof 12